Global Neurology Academy

Identification and Management of Tardive Dyskinesia

ReachMD Healthcare Image
RestartResume
Tardive dyskinesia (TD) can be observed in patients receiving long-term treatment with dopamine receptor blocking agents. As the indications for thes…

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Tardive dyskinesia (TD) can be observed in patients receiving long-term treatment with dopamine receptor blocking agents. As the indications for these agents have expanded, TD is becoming more prevalent. In this activity, an expert reviews TD including risk factors, prevention, and treatment. 

  • Disclosure of Conflicts of Interest

    All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

    Jonathan M. Meyer, MD, consultant: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America Inc., Sunovion Pharmaceuticals, Teva Pharmaceuticals. 

    Amber Hoberg, PMHNP, consultant: Acadia, Avanir, BioXcel, Intracellular Therapies, Neurocrine, Teva.

    Amanda Zimmerman, PA-C, consultant/advisor/speaker: Averitas; researcher: Collegium.

    The planners and content reviewers from Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose except Amber Hoberg, PMHNP and Amanda Zimmerman, PA-C as noted above.

  • Target Audience

    Nps and PAs

  • Learning Objectives

    After completeing this activity, participants should be able to:

    • Identify the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders
    • Describe the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

    In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    ANCC Credit Designation

    Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

    AAPA Credit Designation

    Practicing Clinicans Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 18, 2024. PAs should only claim credit commensurate with the extent of their participation. 

     

    IPCE Credit Designation

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Disclaimer

    The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

  • Provider(s)/Educational Partner(s)

    Provided by Practicing Clinicians Exchange

  • Commercial Support

    Supported by educational grants from Neurocrine Biosciences, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free